Business Context and Reporting Period
This Form 8-K was filed by EyeGate Pharmaceuticals, Inc. (noted as Kiora Pharmaceuticals Inc in metadata) on November 20, 2017. The report addresses a regulatory notice received from The Nasdaq Stock Market regarding the company's compliance with continued listing standards.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it explicitly states the following financial deficiencies relative to Nasdaq requirements:
- Stockholders' Equity: The company failed to maintain the minimum required equity of $2.5 million.
- Market Value of Listed Securities (MVLS): The company failed to meet the alternative standard of $35 million for the previous 30 consecutive business days.
- Net Income: The company failed to meet the alternative standard of $500,000 in net income from continuing operations for the latest fiscal year or two of the last three fiscal years.
Material Changes and Events
The primary material event is the receipt of a delisting notice from Nasdaq on November 20, 2017. The company is currently non-compliant with Nasdaq Listing Rule 5550(b)(1) and its alternative standards (5550(b)(2) and 5550(b)(3)). The notice states there is no present impact on the listing of the company's securities.
Outlook, Risks, and Management Commentary
Compliance Plan: The company must submit a plan to regain compliance to Nasdaq within 45 calendar days of the letter (by approximately December 25, 2017).
Compliance Period: If the plan is accepted, the company has up to 180 calendar days, or until May 19, 2018, to regain compliance by reporting stockholders' equity of at least $2.5 million or meeting the MVLS standard.
Risks: If the company fails to regain compliance or if Nasdaq rejects the plan, the securities will be subject to delisting. The company may appeal such a determination to a hearings panel.
Investor Verification Checklist
- Verify the company's current stockholders' equity balance to assess the gap against the $2.5 million requirement.
- Monitor the submission of the compliance plan to Nasdaq within the 45-day deadline.
- Review the company's strategy to raise capital or improve financial metrics to meet the May 19, 2018 deadline.
- Check for any subsequent filings regarding the acceptance or rejection of the compliance plan by Nasdaq.